Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin

2014 ◽  
Vol 54 (4) ◽  
pp. 462-464 ◽  
Author(s):  
Kathrin Schweda ◽  
Michael Hainz ◽  
Carmen Loquai ◽  
Stephan Grabbe ◽  
Joachim Saloga ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Diagnostic Tool ◽  
Unknown Origin ◽  
Prurigo Nodularis ◽  
Non Hodgkin Lymphoma ◽  
Dermatological Disorders

Patients with Fever of Unknown Origin and Splenomegaly: Diagnostic Value of Splenectomy and Preoperative Risk Factors Suggestive of Underlying Lymphomas

2017 ◽  
Vol 137 (4) ◽  
pp. 240-246
Author(s):  
Lu Zhang ◽  
Wei Zhang ◽  
Huacong Cai ◽  
Xinxin Cao ◽  
Miao Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lymph Nodes ◽  
Hodgkin Lymphoma ◽  
Fever Of Unknown Origin ◽  
Characteristic Curve ◽  
Unknown Origin ◽  
Final Diagnosis ◽  
Diagnostic Value ◽  
Discrimination Power ◽  
Non Hodgkin Lymphoma

Background: We reviewed patients with fever of unknown origin (FUO) and splenomegaly and assessed the diagnostic value of splenectomy and measured risk factors suggestive of an underlying lymphoma. Methods: FUO patients (n = 83) who had splenomegaly and underwent splenectomy were enrolled into this retrospective single-center study. Clinical presentations were documented and risk factors suggestive of an underlying lymphoma were tested. Results: Seventy-four patients (89.2%) had a diagnosis of lymphoma or not after splenectomy and follow-up. Of those (55.4%) diagnosed with lymphoma, 29 had B-cell non-Hodgkin lymphoma and 12 had T-cell non-Hodgkin lymphoma. The remaining 33 (44.6%) had diseases other than lymphoma. Using multivariate logistic analysis, the following 3 independent risk factors were found to be related to a final diagnosis of lymphoma: age (continuous) (HR 1.086; 95% CI 1.033-1.141; p = 0.001), massively enlarged spleen (HR 7.797; 95% CI 1.267-47.959; p = 0.027), and enlarged intra-abdominal lymph nodes (HR 63.925; 95% CI 7.962-513.219; p < 0.001). The calibration of the model was satisfactory (p = 0.248 using the Hosmer-Lemeshow test), and the discrimination power was good (area under the receiver operating characteristic curve 0.925; 95% CI 0.863-0.987). Conclusions: Splenectomy is an effective diagnostic procedure for patients with FUO and splenomegaly and lymphoma is a common cause. Older age, a massively enlarged spleen, and enlarged intra-abdominal lymph nodes are risk factors suggesting an underlying lymphoma, and surgery for high-risk patients should be considered.

scholarly journals Chronic Prurigo: An Unusual Presentation of Hodgkin Lymphoma

2018 ◽  
Vol 10 (2) ◽  
pp. 122-126 ◽  
Author(s):  
Shireen Dumont ◽  
Marc Péchère ◽  
Laurence Toutous Trellu
Keyword(s):  
Hodgkin Lymphoma ◽  
Unknown Origin ◽  
Skin Lesions ◽  
Lymph Node Biopsy ◽  
Prurigo Nodularis ◽  
Laboratory Findings ◽  
Cutaneous Manifestations ◽  
Initial Symptoms ◽  
Intense Pruritus ◽  
Systemic Malignancy

Background: Prurigo nodularis is a condition of unknown origin defined by papulonodular eruption and intense pruritus. Hodgkin lymphoma often presents nonspecific initial symptoms. An association between systemic malignancy and cutaneous manifestations has long been documented. We report a case of prurigo nodularis as a first presentation of Hodgkin lymphoma. Case: A 35-year-old woman presented with a 2-year history of pruritus. Previously diagnosed with bedbugs, the pruritus persisted even after insect eradication, with the appearance of papulonodular lesions consistent with chronic prurigo. The pruritus and the pain were refractory to all treatments. She had no past medical history or clinical, radiological, or laboratory findings. A lymphadenopathy was revealed 2 years after onset of the symptoms. Lymph node biopsy showed a nodular sclerosis Hodgkin lymphoma. The patient was initiated on chemotherapy and the skin lesions decreased. Conclusion: This case report of chronic prurigo as the first manifestation of a systemic malignancy reminds us of the importance of a systematic diagnostic approach to this kind of patients initially and throughout time, especially if the symptoms do not respond to treatment. Our case may question the role of imaging examinations in the management and follow-up of a persistent prurigo nodularis.

scholarly journals Non-Hodgkin Lymphoma Associated Eczema and Prurigo Nodularis: A Case Report

2018 ◽  
Vol 12 (2) ◽  
pp. 107-109
Author(s):  
Mehdi Iskandarli ◽  
İlgen Ertam ◽  
Banu Yaman
Keyword(s):  
Case Report ◽  
Hodgkin Lymphoma ◽  
Prurigo Nodularis ◽  
Non Hodgkin Lymphoma

Studies on relativity of p73 gene methylation and non-Hodgkin lymphoma

2010 ◽  
Vol 34 (8) ◽  
pp. S48-S48
Author(s):  
Jing‑Hong Pei ◽  
Sai‑Qun Luo ◽  
Jiang‑Hua Chen ◽  
Hua‑Wu Xiao ◽  
Wei‑Xin Hu
Keyword(s):  
Hodgkin Lymphoma ◽  
Gene Methylation ◽  
Non Hodgkin Lymphoma ◽  
P73 Gene

Evaluation of R-CHOP and R-CVP in the treatment of elderly patient with non-Hodgkin lymphoma

MedPharmRes ◽  
2019 ◽  
Vol 3 (3) ◽  
pp. 1-6
Author(s):  
Truc Phan ◽  
Tram Huynh ◽  
Tuan Q. Tran ◽  
Dung Co ◽  
Khoi M. Tran
Keyword(s):  
Elderly Patients ◽  
Hodgkin Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
The Elderly ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Common Sign ◽  
Related Mortality

Introduction: Little information is available on the outcomes of R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) in treatment of the elderly patients with non-Hodgkin lymphoma (NHL), especially in Vietnam. Material and methods: All patients were newly diagnosed with CD20-positive non-Hodgkin lymphoma (NHL) at Blood Transfusion and Hematology Hospital, Ho Chi Minh city (BTH) between 01/2013 and 01/2018 who were age 60 years or older at diagnosis. A retrospective analysis of these patients was perfomed. Results: Twenty-one Vietnamese patients (6 males and 15 females) were identified and the median age was 68.9 (range 60-80). Most of patients have comorbidities and intermediate-risk. The most common sign was lymphadenopathy (over 95%). The proportion of diffuse large B cell lymphoma (DLBCL) was highest (71%). The percentage of patients reaching complete response (CR) after six cycle of chemotherapy was 76.2%. The median follow-up was 26 months, event-free survival (EFS) was 60% and overall survival (OS) was 75%. Adverse effects of rituximab were unremarkable, treatment-related mortality accounted for less than 10%. There was no difference in drug toxicity between two regimens. Conclusions: R-CHOP, R-CVP yielded a good result and acceptable toxicity in treatment of elderly patients with non-Hodgkin lymphoma. In patients with known cardiac history, omission of anthracyclines is reasonable and R-CVP provides a competitive complete response rate.

Sign in / Sign up

Export Citation Format

Share Document